Education
About Us
Working with TipRanks
Follow Us
Eton Pharmaceuticals (ETON)
:ETON
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
<0.01Last Year’s EPS
-0.12Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: -1.35%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
Eton Pharmaceuticals demonstrated strong revenue growth and successful product launches, particularly with Increlex and Galzin. However, the company faces challenges with increased operating expenses and a net loss for the quarter. Despite these lowlights, the overall performance and future prospects indicate a positive trend.Company Guidance
During Eton Pharmaceuticals' first quarter 2025 financial results conference call, CEO Sean Brynjelsen highlighted significant growth and strategic initiatives. Eton reported a 117% year-over-year revenue increase to $17.3 million, driven by product sales and licensing revenue. The company emphasized the potential of its new acquisitions, Increlex and Galzin, which have shown promising results, with Increlex reaching over 90 active patients. Eton aims to expand its product reach by harmonizing U.S. and EU labels, potentially benefiting up to 1,000 U.S. patients. The company is also preparing for the launch of ET-400, targeting a significant market opportunity in adrenal insufficiency, with a PDUFA date set for May 28. Eton's robust pipeline and strategic partnerships position it for continued growth, with expectations to reach a $100 million revenue run rate in the near term. Adjusted gross margins are projected to exceed 75% by 2028.Strong Revenue Growth
Eton Pharmaceuticals reported a first quarter revenue of $17.3 million, an increase of 117% compared to the first quarter of 2024.
Successful Product Launches
The acquisition and relaunch of Increlex and Galzin have been successful, with Increlex reaching over 90 active patients, reversing a declining trend.
Pipeline Advancements
Eton has advanced its pipeline candidates, with two potential approvals expected in the next 9 months, including ET-400 with a PDUFA date of May 28.
Out-licensing of Increlex International Rights
Eton licensed Increlex's international rights to Esteve Pharmaceuticals for $4.3 million, improving profitability and reinvesting in pipeline opportunities.
Strong Cash Flow
Eton generated $2.1 million of operating cash flow during the quarter and finished with $17.4 million of cash-on-hand.
ETON Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ETON Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $17.07 | $17.12 | +0.29% |
Mar 18, 2025 | $15.29 | $14.68 | -3.99% |
Nov 12, 2024 | $9.17 | $10.60 | +15.59% |
Aug 08, 2024 | $3.62 | $3.72 | +2.76% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Eton Pharmaceuticals (ETON) report earnings?
Eton Pharmaceuticals (ETON) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Eton Pharmaceuticals (ETON) earnings time?
Eton Pharmaceuticals (ETON) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ETON EPS forecast?
ETON EPS forecast for the fiscal quarter 2025 (Q2) is <0.01.
